Table 1.
Baseline characteristics of the study cohort.
| Total study cohort | Group without SARS-CoV-2 infection | Group with SARS-CoV-2 infection | P-value | |
|---|---|---|---|---|
| (n = 199,219) | (n = 197,342) | (n = 1,877) | ||
| BNT162b2 doses received, n (%) | ||||
| One dose | 129,462 (65%) | 129,950 (65%) | 1512 (80.5%) | |
| Two doses | 69,757 (35%) | 69,392 (35%) | 365 (19.5%) | |
| Female, n (%) | 83,034 (41.7%) | 82,214 (41.7%) | 820 (43.7%) | 0.076 |
| Age (years) | 42 (33–55) | 42 (33–55) | 44 (35–54) | <0.001 |
| Age groups (years), n (%) | ||||
| 16–24 | 13,826 (6.9%) | 13,764 (7%) | 62 (3.3%) | |
| 25–34 | 43,302 (21.7%) | 42,934 (21.8%) | 368 (19.6%) | |
| 35–44 | 51,934 (26.1%) | 51,384 (26%) | 550 (29.3%) | |
| 45–54 | 39,274 (19.7%) | 38,823 (19.7%) | 451 (24%) | |
| 55–64 | 31,257 (15.7%) | 30,978 (15.7%) | 279 (14.9%) | |
| ≥65 | 19,626 (9.9%) | 19,459 (9.9%) | 167 (8.9%) | |
| Co-existing medical conditions | ||||
| Diabetes mellitus | 39,994 (20.1%) | 39,550 (20%) | 444 (23.7%) | <0.001 |
| Hypertension | 42,994 (21.6%) | 42,512 (21.5%) | 482 (25.7%) | <0.001 |
| Chronic heart disease | 10,308 (5.2%) | 10,190 (5.2%) | 118 (6.3%) | <0.029 |
| Chronic lung disease | 19,477 (9.8%) | 19,270 (9.8%) | 207 (11%) | 0.067 |
| Chronic kidney disease | 4272 (2.1%) | 4209 (2.13%) | 63 (3.4%) | <0.001 |
| Chronic liver disease | 1781 (0.9%) | 1754 (0.9%) | 27 (1.4%) | 0.012 |
| Malignant disease | 3724 (1.9%) | 3691 (1.9%) | 33 (1.8%) | 0.72 |
| Organ transplant recipient | 653 (0.33%) | 640 (0.32%) | 13 (0.69%) | 0.005 |
Data are presented as number (%) or median (interquartile range). P-values were derived from Pearson’s chi-squared or Wilcoxon rank-sum test, as appropriate.